|
|
|
|
Grannus BioSciences LTD • Privately held biotechnology company incorporated January 2004 under the Companies Acts in Scotland Registration Number SC240992 • Clinical stage novel anti-inflammatory products • Exclusive World Wide License from the University of Glasgow to issued and pending patents • Managed by Pharmetix Corp. of California, U.S.A. • Corporate Counsel, Dundas & Wilson, Glasgow www.grannusbiosciences.com
Grannus 2004-2005 • Grannus BioSciences Limited Announces Appointment of EGeen as CRO • Grannus BioSciences Ltd. Announces Agreement for Preclinical and Clinical Stage Molecules • Grannus receives a SCIS award from Targeting Innovation • Grannus to file IND/CTA for human clinical testing • Grannus receives Business Growth Fund Award from Scottish Enterprise • Grannus receives Notice of Allowance in Australia and China for its patent applications • Grannus appoints Iain McInnes and Robin Stevenson, Royal Infirmary Scotland and Dr. Minnie McMillan, USC School of Medicine to the Scientific Advisory Board
|
GRANNUS BIOSCIENCES LTD. ANNOUNCES AGREEMENT October 19, 2005 —- Grannus BioSciences Ltd, a privately held biotechnology company developing anti-inflammatory products, announced today two separate agreements with Strathclyde University the first involving a clinical stage compound for use in certain dermatologic and cancer applications. Under a second and separate agreement, Grannus will have an option to as many as six small molecules for development as potential anti-inflammatory pharmaceuticals. The company will collaborate with the Strathclyde Institute for Drug Research (SIDR) which discovered the compounds. Financial terms were not disclosed. Dr. Elizabeth McLaughlin Taylor, Chief Operating Officer of the Company, said: “We are pleased to have reached the agreements with Strathclyde University which effectively expand Grannus’ pipeline of anti-inflammatory products with the molecules from SIDR’s extensive plant derived library. We are also excited at the prospect of moving the clinical stage product into Phase II testing next year. These compounds complement nicely the Company’s current technology portfolio based on thymosin beta 4 sulfoxide, for which Grannus holds a worldwide exclusive license from Glasgow University.” Grannus BioSciences, formed in 2004, is developing products for application to dermatologic, respiratory and other inflammatory disorders. The Company’s lead biologic, thymosin beta 4 sulfoxide, is an anti-inflammatory biologic for which Grannus plans to initiate clinical testing in dermatologic disease. For further information, please contact Dr. Elizabeth McLaughlin Taylor at ir@grannusbiosciences.com or visit www.grannusbiosciences.com
|
|